Sandbox/00007: Difference between revisions

Jump to navigation Jump to search
Line 205: Line 205:
* [[intravenous therapy|IV]] bolus [[normal saline]] should be waived in the presence of [[pulmonary edema]].
* [[intravenous therapy|IV]] bolus [[normal saline]] should be waived in the presence of [[pulmonary edema]].


* [[Norepinephrine]]
* '''[[Norepinephrine]]'''
:* ''Dosage and Administration''
:* ''Dosage and Administration''
::* Mix 1 ampule (4 mg) in 250 mL of [[Intravenous sugar solution|D5W]] or [[Intravenous sugar solution|D5NS]].  
::* Mix 1 ampule (4 mg) in 250 mL of [[Intravenous sugar solution|D5W]] or [[Intravenous sugar solution|D5NS]].  
Line 211: Line 211:
::* Avoid dilution in [[normal saline]] alone.
::* Avoid dilution in [[normal saline]] alone.
::* Do not administer in same IV line as alkaline solutions.
::* Do not administer in same IV line as alkaline solutions.
:* ''Indications''
:* ''Indications''
::* For severe [[cardiogenic shock]] and [[hemodynamic|hemodynamically]] significant hypotension ([[SBP]] <70 mm Hg) with a low systemic vascular resistance.
::* For severe [[cardiogenic shock]] and [[hemodynamic|hemodynamically]] significant hypotension ([[SBP]] <70 mm Hg) with a low systemic vascular resistance.

Revision as of 22:21, 18 April 2014

Cardiogenic Shock
Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, MBChB. [2]

Overview

The clinical definition of cardiogenic shock includes decreased cardiac output with evidence of tissue hypoxia in the presence of adequate intravascular volume.[1]

Causes

Life Threatening Causes

Cardiogenic shock is a life-threatening condition and must be treated as such irrespective of the underlying cause.

Common Causes

  • Arrhythmic
  • Mechanical
  • Myopathic
  • Pharmacologic

Click here for the complete list of causes.

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.

Boxes in the salmon color signify that an urgent management is needed.

Abbreviations: CBC, complete blood count; CI, cardiac index; CK-MB, creatine kinase MB isoform; CVP, central venous pressure; DC, differential count; ICU, intensive care unit; INR, international normalized ratio; LFT, liver function test; MAP, mean arterial pressure; MVO2, mixed venous oxygen saturation; PCWP, pulmonary capillary wedge pressure; PT, prothrombin time; PTT, partial prothrombin time; SaO2, arterial oxygen saturation; SBP, systolic blood pressure; SCVO2, central venous oxygen saturation; SMA-7, sequential multiple analysis-7.

 
 
 
 
Does the patient have cardinal findings that increase the pretest probability of cardiogenic shock?

❑  Evidence of hypoperfusion

❑  Altered mental status
❑  Cool extremities
❑  Cyanosis
❑  Oliguria
❑  Sustained hypotension
❑  SBP <90 mm Hg for ≥30 min or
❑  MAP ↓ >30 mm Hg below baseline for ≥30 min
❑  Presence of myocardial dysfunction after exclusion or correction of non-myocardial factors contributing to tissue hypoperfusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiogenic
shock
suspected
 
 
 
 
 
Proceed to
shock resident survival guide
to identify and correct the cause
 
 
 
 
 
 
 
 
 
 
 
 
Immediate management (click for details)

❑  Intubation with mechanical ventilation

❑  ± Normal saline IV bolus 100–200 mL

❑  ± Norepinephrine IV infusion 0.1–2.0 μg/kg/min

❑  ± Morphine 2–4 mg IV push slowly (in 1–5 min)

❑  Hold antihypertensive medications

❑  Cardiology consultation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediate goals

❑  SaO2 >90%–92%

❑  CVP 8–12 mm Hg

❑  MAP >60 mm Hg

❑  PCWP 14–18 mm Hg

❑  CI >2.2 L/min/m2

❑  MVO2 >60%

❑  SCVO2 >70%

❑  Hemoglobin >7–9 g/dL

❑  Lactate <2.2 mM/L

❑  Urine output >0.5 mL/kg/h

❑  ± Correct arrhythmia

❑  ± Correct electrolyte disturbance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Complete Diagnostic Approach

Treatment

Do's

Diagnostic criteria

Immediate management

  • Dosage and Administration
  • Mix 1 ampule (4 mg) in 250 mL of D5W or D5NS.
  • IV infusion 0.5–1.0 μg/min titrated to improve blood pressure (up to 30 μg/min).
  • Avoid dilution in normal saline alone.
  • Do not administer in same IV line as alkaline solutions.
  • Indications
  • For severe cardiogenic shock and hemodynamically significant hypotension (SBP <70 mm Hg) with a low systemic vascular resistance.
  • This is an agent of last resort for management of ischemic heart disease and shock.

Don'ts

References

  1. 1.0 1.1 1.2 Califf, RM.; Bengtson, JR. (1994). "Cardiogenic shock". N Engl J Med. 330 (24): 1724–30. doi:10.1056/NEJM199406163302406. PMID 8190135. Unknown parameter |month= ignored (help)
  2. Hollenberg, SM.; Kavinsky, CJ.; Parrillo, JE. (1999). "Cardiogenic shock". Ann Intern Med. 131 (1): 47–59. PMID 10391815. Unknown parameter |month= ignored (help)
  3. 3.0 3.1 Goldberg, RJ.; Gore, JM.; Alpert, JS.; Osganian, V.; de Groot, J.; Bade, J.; Chen, Z.; Frid, D.; Dalen, JE. (1991). "Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988". N Engl J Med. 325 (16): 1117–22. doi:10.1056/NEJM199110173251601. PMID 1891019. Unknown parameter |month= ignored (help)
  4. Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts)". N Engl J Med. 295 (24): 1356–62. doi:10.1056/NEJM197612092952406. PMID 790191. Unknown parameter |month= ignored (help)
  5. Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts)". N Engl J Med. 295 (25): 1404–13. doi:10.1056/NEJM197612162952505. PMID 790194. Unknown parameter |month= ignored (help)
  6. Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)